Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | OGG1 | O15527 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17231392 | 0.86 | KDM4E (0.68) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL17231393 | 0.83 | KDM4E (0.73) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL7351663 | 0.83 | KDM4E (0.53) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL9356896 | 0.81 | KDM4E (0.52) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL7354510 | 0.80 | KDM4E (0.50) | KDM4ERAB9APOLBKMT2AALDH1A1 | |
| SCHEMBL9356593 | 0.78 | KDM4E (0.48) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL2599771 | 0.76 | KDM4E (0.51) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL18222986 | 0.76 | KDM4E (0.61) | KDM4ERAB9APOLBKMT2AMEN1 | |
| SCHEMBL12218414 | 0.76 | KDM4E (0.86) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL17235944 | 0.76 | KDM4E (0.57) | KDM4ERAB9APOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-10 | — | — | US | claimed |
| US-12545722-B2 | Pharmaceutical compositions targeting immune-mediated processes in neurodegenerative disease | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-10 | — | — | US | claimed |
| US-20250345644-A1 | FIRE RETARDANT COMPOSITIONS CONTAINING A CARBONATE SALT AND ONE OR MORE CORROSION INHIBITORS | PERIMETER SOLUTIONS LP | 2025-11-13 | — | — | US | claimed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240352106-A1 | PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-24 | — | — | US | claimed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| EP-4211732-A1 | ELECTROCHEMICAL CELLS, COMPONENTS THEREOF, AND METHODS OF THEIR MANUFACTURE | Alsym Energy, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| EP-1487431-A4 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORP LTD (NZ) | 2006-10-25 | — | — | EP | claimed |
| US-20050227369-A1 | Rapid analysis of functional fluids | THE LUBRIZOL CORPORATION, A CORPORATION OF THE STATE OF OHIO (US) | 2005-10-13 | — | — | US | claimed |
| US-6951890-B2 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORPORATION LIMITED (NZ) | 2005-10-04 | — | — | US | claimed |
| CN-1649577-A | Preventing and/or treating cardiovascular disease and/or associated heart failure | PROTEMIX CORP LTD (NZ) | 2005-08-03 | — | — | CN | claimed |
| EP-1487431-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | Protemix Corporation Limited (NZ) | 2004-12-22 | — | — | EP | claimed |
| WO-2004017957-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2004-03-04 | — | — | WO | claimed |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | PHILERA NEW ZEALAND LIMITED (NZ) | 2003-10-30 | — | — | US | claimed |
| WO-2003077901-A1 | PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASE AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-25 | — | — | WO | claimed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | claimed |
| US-20030044360-A1 | Process and composition for high efficacy teeth whitening | SCIENTIFIC PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545722-B2 | Pharmaceutical compositions targeting immune-mediated processes in neurodegenerative disease | PMP22, CDR2, CD79B | KDM4E 666/4885RAB9A 1871/4885POLB 265/4885 |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | LDLR, MSR1, LOXL1 | KDM4E 1845/4885RAB9A 1615/4885POLB 1155/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | KDM4E 3314/4885RAB9A 1701/4885POLB 2679/4885 |
| US-20030203973-A1 | Preventing and/or treating cardiovascular disease and/or associated heart failure | TNNI3, FABP3, TNNT2 | KDM4E 3347/4885RAB9A 4323/4885POLB 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.